Putative role of hepatitis B virus X protein in hepatocarcinogenesis: Effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue 4, 2000, Pages 357-368

  Arbuthnot, Patrick ^a   Capovilla, Alexio ^a   Michael, Kew ^a  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

Author keywords

Apoptosis; DNA repair; HBx; Hepatitis B virus; Janus kinases signal transducer and activators of transcription (JAK STAT); Mitogen activated protein kinase; p53

Indexed keywords

DNA BINDING PROTEIN; HEPATITIS B VIRUS X PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; STAT PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

APOPTOSIS; CANCER RISK; CELL PROLIFERATION; DNA REPAIR; EXCISION REPAIR; HEPATITIS B; HEPATITIS B VIRUS; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MALIGNANT TRANSFORMATION; NONHUMAN; OPEN READING FRAME; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TRANSACTIVATION; VIRUS GENOME;

EID: 0034099208     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02069.x     Document Type: Review

References (130)

1. Szmuness W. Hepatocellular carcinoma and the hepatitis B virus: Evidence for a causal association. Prog. Med. Virol. 1979; 24: 40-69.
2. Beasley RP, Lin CC, Hwang LY, Chien CS. Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22707 men in Taiwan. Lancet 1981; ii: 1129-33.
3. Robinson WS. Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. Anna. Rev. Med. 1994; 45: 297-323.
4. Feitelson M. Hepatitis B virus infection and primary hepatocellular carcinoma. Clin. Microbiol. Rev. 1992; 5: 275-301.
5. Mason WS, Aldrich C, Summers J, Taylor JM. Asymmetric replication of duck hepatitis B virus DNA in liver cells: Free minus-strand DNA. Proc. Natl Acad. Sci. USA 1982; 79: 3997-4001.
6. Weiser B, Ganem D, Seeger C, Varmus HE. Closed circular viral DNA and asymmetric heterogeneous forms in livers from animals infected with ground squirrel hepatitis virus. J. Virol. 1983; 48: 1-9.
7. Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1985; 317: 489-95.
8. Ruiz-Opazo N, Chakraborty PR, Shafritz DA. Evidence for supercoiled hepatitis B virus DNA in chimpanzee liver and serum Dane particles: Possible implications in persistent HBV infection. Cell 1982; 29: 129-36.
9. Mason WS, Halpern MS, England JM et al. Experimental transmission of duck hepatitis B virus. Virology 1983; 131: 375-84.
10. Schaller H, Fischer M. Transcriptional control of hepadnavirus gene expression. In: Mason WS, Seeger C, eds. Hepadnaviruses: Molecular Biology and Pathogenesis. Berlin: Springer-Verlag, 1991; 21-39.
11. Seeger C, Ganem D, Varmus HE. Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science 1986; 232: 477-84.
12. Ganem D. Assembly of hepadnaviral virions and subviral particles. In: Mason WS, Seeger C, eds. Hepadnaviruses: Molecular Biology and Pathogenesis. Berlin: Springer-Verlag, 1991; 61-83.
13. Miller RH, Robinson WS. Common evolutionary origin of hepatitis B virus and retroviruses. Proc. Natl Acad. Sci. USA 1986; 83: 2531-5.
14. Chen H-S, Kaneko S, Girones R et al. The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J. Virol. 1993; 67: 1218-26.
15. Zoulim F, Saputelli J, Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J. Virol. 1994; 68: 2026-30.
16. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317-20.
17. Ullrich SJ, Zeng ZZ, Jay G. Transgenic mouse models of human gastric and hepatic carcinomas. Semin. Cancer Biol. 1994; 5: 61-8.
18. Koike K, Moriya K, Iino S et al. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 1994; 19: 810-19.
19. Koike K. Hepatitis B virus HBx gene and hepatocarcinogenesis. Intervirology 1995; 38: 134-42.
20. Slagle BL, Lee TH, Medina D, Finegold MJ, Butel JS. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Mol. Carcinog. 1996; 15: 261-9.
21. Billet O, Grimbler G, Levrero M, Seye KA, Briand P, Joulin V. In vivo activity of the hepatitis B virus core promoter: Tissue specificity and temporal regulation. J. Virol. 1995; 69: 5912-16.
22. Terradillos O, Billet O, Renard CA et al. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 1997; 14: 395-404.
23. Paterlini P, Poussin K, Kew M, Franco D, Brechet C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B virus surface antigen with hepatocellular carcinoma. Hepatology 1995; 21: 313-21.
24. Miyaki M, Sato C, Gotanda T et al. Integration of region X of hepatitis B virus genome in human primary hepatocellular carcinomas propagated in nude mice. J. Gen. Virol. 1986; 67: 1449-54.
25. Su Q, Schröder CH, Hofmann WJ, Otto G, Pichlmayr R, Bannasch P. Expression of hepatitis B virus X protein in HBV-infected human livers and hepatocellular carcinoma. Hepatology 1998; 27: 1109-20.
26. Sirma H, Weil R, Rosmorduc O et al. Cytosol is the prime compartment of hepatitis B virus X protein where it colocalises with the proteasome. Oncogene 1998; 16: 2051-63.
27. Jin L, Zhang HQ, Ma XK, Chen DH, Gue YJ, Wu MC. Detection of HBxAg in liver specimens of patients with hepatocellular carcinoma. Chin. J. Pathol. 1990; 19: 288-90.
28. Zentgraf H, Hermann G, Klein R et al. Mouse monoclonal antibody directed against hepatitis B virus X protein synthesised in Escherichia coli: Detection of reactive antigen in liver cell carcinoma and chronic hepatitis. Oncology 1990; 47: 143-8.
29. Haruna Y, Hayashi N, Katayama K et al. Expression of X protein and hepatitis B virus replication in chronic hepatitis. Hepatology 1991; 13: 417-21.
30. Nomura T, Lin Y, Dorjsuren D, Ohno S, Yamashita T, Murakami S. Human hepatitis B virus X protein is detectable in nuclei of transfected cells, and is active for transactivation. Biochim. Biophys. Acta 1999; 1453: 330-40.
31. Doria M, Klein N, Lucito R, Schneider RJ. The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBO J. 1995; 14: 4747-57.
32. Rossner MT. Hepatitis B virus X-gene product: A promiscuous transcriptional activator. J. Med. Virol. 1992; 36: 101-17.
33. Caselmann WH. Transactivation of cellular genes by hepatitis B virus proteins: A possible mechanism of hepatocarcinogenesis. Adv. Virus Res. 1996; 47: 253-302.
34. Yen TSB. Hepadnaviral X protein: Review of recent progress. J. Biomed. Sci. 1996; 3: 20-30.
35. Ellis RE, Yuan J, Horvitz HR. Mechanisms and functions of cell death. Annu. Rev. Cell Biol. 1991; 7: 663-98.
36. Wertz IE, Hanley MR. Diverse molecular provocation of programmed cell death. Trends Biochem. Sci. 1996; 21: 359-64.
37. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-65.
38. Earnshaw WC. A cellular poison cupboard. Nature 1999; 397: 387-9.
39. Muzio M, Chinnaiyan AM, Kishkel FC et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (FAS/APO-1) death-inducing signaling complex. Cell 1996; 85: 817-27.
40. Yang X, Khosravi R, Chang HY, Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 1997; 89: 1067-76.
41. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease in Fas/APO-1 and TNF receptor-induced cell death. Cell 1996; 85: 803-15.
42. Liu XS, Zou H, Slaughter C, Wang XD. DNA fragmentation factor. A heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 1997; 89: 175-84.
43. Korsmeyer S. Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 1992; 80: 879-86.
44. Reed J. Bcl-2 and the regulators of cell death. J. Cell Biol. 1994; 124: 1-6.
45. Yang J, Liu X, Bhalla K et al. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-32.
46. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science 1997; 275: 1132-6.
47. Oltvai ZN, Millman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-19.
48. Oren M. Relationship of p53 to the control of apoptotic cell death. Semin. Cancer Biol. 1994; 5: 221-7.
49. White E. Life, death, and the pursuit of apoptosis. Genes Dev. 1996; 10: 1-15.
50. WAF1 CIP1 -/-human cancer cells. Cancer Res. 1996; 56: 2250-5.
51. waf1 cip1 protein associates with the detergent-insoluble form of PCNA concomitantly with disassembly of PCNA at nucleotide excision repair sites. Oncogene 1996; 13: 1591-8.
52. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389: 300-5.
53. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-9.
54. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
55. Prives C. Signaling to p53: Breaking the MDM2-p53 circuit. Cell 1998; 95: 5-8.
56. Lau JYN, Xie X, Lai MMC, Wu PC. Apoptosis and viral hepatitis. Semin. Liver Dis. 1998; 18: 169-76.
57. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-9.
58. Wang XW, Gibson MK, Vermeulen W et al. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res. 1995; 55: 6012-16.
59. Elmore LW, Hancock AR, Chang S-F et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc. Natl Acad. Sci. USA 1997; 94: 14707-12.
60. Takada S, Koike K. X protein of hepatitis B virus resembles a serine protease inhibitor. Jpn. J. Cancer Res. 1990; 81: 1191-4.
61. Gottlob K, Fulco M, Levrero M, Graessmann A. The hepatitis B virus HBx protein inhibits caspase 3 activity. J. Biol. Chem. 1998; 273: 33 347-53.
62. Pollicino T, Terradillos O, Lecoeur H, Gougeon ML, Buendia MA. Pro-apoptotic effect of the hepatitis B virus X gene. Biomed. Pharmacother. 1998; 52: 363-8.
63. Terradillos O, Pollicino T, Lecoeur H et al. p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro. Oncogene 1998; 17: 2115-23.
64. Koike K, Moriya K, Yotsuyanagi H et al. Compensatory apoptosis in preneoplastic liver of a transgenic mouse model for viral hepatocarcinogenesis. Cancer Lett. 1998; 134: 181-6.
65. Su F, Schneider RJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor α. Proc. Natl Acad. Sci. USA 1997; 94: 8744-9.
66. Sheron N, Lau JYN, Daniels H et al. Increased production of tumour necrosis factor alpha in chronic HBV infection. J. Hepatol. 1991; 12: 241-5.
67. Yoshioka K, Kakumu S, Arao M, Tsutsumi Y, Inoue M. Tumor necrosis factor alpha production in peripheral mononuclear cells of patients with chronic liver disease. Hepatology 1989; 10: 769-73.
68. Lau JYN, Sheron N, Kayhan KT, Alexander GJM, Williams R. Increased tumor necrosis factor-alpha receptor number in chronic hepatitis B virus (HBV) infection. Hepatology 1991; 14: 44-50.
69. Kim H, Lee H, Yun Y. X-gene product of hepatitis B virus induces apoptosis in liver cells. J. Biol. Chem. 1998; 273: 381-5.
70. Sarnow P, Ho YS, Williams J, Levine AJ. Adenovirus E1b-58 kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 1982; 28: 387-94.
71. Linzer DI, Levine AJ. Characterisation of a 54 kilodalton cellular SV40 tumor antigen present in sv40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17: 43-52.
72. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248: 76-9.
73. Lowe SW, Ruley HE. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev. 1993; 7: 535-45.
74. Debbas M, White E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 1993; 7: 546-54.
75. Schaak J, Maguire HF, Siddiqui A. Hepatitis B virus X protein partially substitutes for E1A transcriptional function during adenoviral infection. Virology 1996; 216: 425-30.
76. Balsano C, Avataggiati ML, Natoli G et al. Full-length and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the c-myc proto-oncogene at the transcriptional level. Biochem. Biophys. Res. Commun. 1991; 176: 985-92.
77. Feitelson MA, Zhu M, Duan L-X, London WT. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993; 8: 1109-17.
78. Ueda H, Ullrich SJ, Gangemi JD et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nature Genet. 1995; 9: 41-7.
79. Henkler F, Waseem N, Golding MHC, Alison MR, Koshy R. Mutant p53 but not hepatitis B virus X protein is present in hepatitis B virus related human hepatocellular carcinoma. Cancer Res. 1995; 55: 6084-91.
80. Geenblatt MS, Feitelson MA, Zhu M et al. Integrity of p53 in hepatitis B x antigen-positive and -negative hepatocellular carcinomas. Cancer Res. 1997; 57: 426-32.
81. Okuda T, Hirohashi K, Kinoshita H, Wakasa K, Sakurai M. Characteristic histologic features of human hepatocellular carcinoma with mutant p53 protein. World J. Surg. 1996; 20: 215-20.
82. Schaff Z, Sarosi I, Hsia CC, Kiss A, Tabor E. p53 in malignant and benign liver lesions. Eur. J. Cancer 1995; 31A: 1847-50.
83. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl Acad. Sci. USA 1994; 15: 2230-4.
84. Takada S, Tsuchida N, Kobayashi M, Koike K. Disruption of the function of tumour-suppressor gene p53 by the hepatitis B virus X protein and hepatocarcinogenesis. J. Cancer Res. Clin. Oncol. 1995; 121: 593-601.
85. Reed M, Woelker B, Wang P, Wang Y, Anderson ME, Tegtmeyer P. The C-terminal domain of p53 recognises DNA damaged by ionising radiation. Proc. Natl Acad. Sci. USA 1995; 92: 9455-9.
86. Wang Y, Reed M, Wang P et al. p53 domains: Identification and characterization of two autonomous DNA-binding regions. Genes Dev. 1993; 7: 2575-86.
87. Lin Y, Nomura T, Yamashita T, Dorjsuren D, Tang H, Murakami S. The transactivation and p53-interacting functions of hepatitis B virus X protein are mutually interfering but distinct. Cancer Res. 1997; 57: 5137-42.
88. Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J. Virol. 1995; 69: 1851-9.
89. Taylor EM, Lehmann AR. Review. Conservation of eukaryotic DNA repair mechanisms. Int. J. Radiat. Biol. 1998; 74: 277-86.
90. Wood RW. Nucleotide excision repair in mammalian cells. J. Biol. Chem. 1997; 272: 23465-8.
91. Wang XW, Yeh H, Schaeffer L et al. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nature Genet. 1995; 10: 188-95.
92. Hwang BJ, Chu G. Purification and characterization of a human protein that binds to damaged DNA. Biochemistry 1993; 32: 1657-66.
93. Keeney S, Eker APM, Brody T et al. Correction of the DNA repair defect in xeroderma pigmentosum group E by injection of a DNA damage-binding protein. Proc. Natl Acad. Sci. USA 1994; 91: 4053-6.
94. Aboussekhra A, Biggerstaff M, Shivji M et al. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell 1995; 80: 859-68.
95. Prost S, Ford JM, Taylor C, Doig J, Harrison DJ. Hepatitis B x protein inhibits p53-dependent DNA repair in primary mouse hepatocytes. J. Biol. Chem. 1998; 273: 33 327-32.
96. Jia L, Wang XW, Harris CC. Hepatitis B virus X protein inhibits nucleotide excision repair. Int. J. Cancer 1999; 80: 875-9.
97. Groisman IJ, Koshy R, Henkler F, Groopman JD, Alaoui-Jamali MA. Downregulation of DNA excision repair by the hepatitis B virus-x protein occurs in p53-proficient and p53-deficient cells. Carcinogenesis 1999; 20: 479-83.
98. Capovilla A, Carmona S, Arbuthnot P. Hepatitis B virus X protein binds damaged DNA and sensitizes liver cells to ultraviolet irradiation. Biochem. Biophys. Res. Commun. 1997; 232: 255-60.
99. Lee T, Elledge SJ, Butel JS. Hepatitis B virus X protein interacts with a probable cellular DNA repair protein. J. Virol. 1995; 69: 1107-14.
100. Becker SA, Lee T, Butel JS, Slagle BL. Hepatitis B virus X protein interferes with cellular DNA repair. J. Virol. 1998; 72: 266-72.
101. Krishnamoorthy RR, Lee T, Butel JS, Das HK. Apolipoprotein B gene regulatory factor-2 (BRF-2) is structurally and immunologically highly related to hepatitis B virus X associated protein-1 (XAP-1). Biochemistry 1997; 36: 960-9.
102. Hayes S, Shiyanov P, Chen X, Raychaudhuri P. DDB, a putative DNA repair protein, can function as a transcriptional partner of E2F1. Mol. Cell. Biol 1998; 18: 240-9.
103. Qadri I, Conaway JW, Conaway RC, Schaack J, Siddiqui A. Hepatitis B virus transactivator protein, HBx, associates with the components of TFIIH and stimulates the DNA helicase activity of TFIIH. Proc. Natl Acad. Sci. USA 1996; 93: 10578-83.
104. Blum HE, Zhang Z, Galun E et al. Hepatitis B virus x protein is not central to the viral life cycle in vitro. J. Virol. 1992; 66: 1223-7.
105. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J. Biol.Chem. 1993; 268: 14 553-6.
106. Denhardt DT. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: The potential for multiplex signaling. Biochem. J. 1996; 318: 729-47.
107. Tomlinson A, Ready DF. Sevenless: A cell-specific homeotic mutation of the Drosophila eye. Science 1986; 231: 400-2.
108. Rogge RD, Karlovich CA, Banerjee U. Genetic dissection of a neurodevelopmental pathway: Son of Sevenless functions downstream of sevenless and EGF receptor tyrosine kinases. Cell 1991; 64: 39-48.
109. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene 1998; 17: 1395-413.
110. Rommel C, Haffen E. Ras: A versatile cellular switch. Curr. Opin. Genet. Dev. 1998; 8: 412-18.
111. Kekule AS, Lauer U, Weiss L, Luber B, Hofschneider PH. Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature 1993; 361: 742-5.
112. Luber B, Lauer U, Weiss L, Hohne M, Hofschneider PH, Kekule AS. The hepatitis B virus transactivator HBx causes elevation of diacylglycerol and activation of protein kinase C. Res. Virol. 1993; 144: 311-21.
113. Cross JC, Wen P, Rutter WJ. Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/threonine kinases. Proc. Natl Acad. Sci. USA 1993; 90: 8078-82.
114. Natoli G, Avantaggiati ML, Chirillo P et al. Ras-and Raf-dependent activation of c-Jun transcriptional activity by the hepatitis B virus transactivator pX. Oncogene 1994; 9: 2837-43.
115. Murakami S, Cheong J, Ohno S, Matsushima K, Kaneko S. Transactivation of human hepatitis B virus X protein, HBx, operates through a mechanism distinct from protein kinase C and okadaic acid activation pathways. Virology 1994; 199: 243-6.
116. Lucito R, Schneider RJ. Hepatitis B virus X protein activates transcription factor NF-κB without a requirement for protein kinase C. J. Virol. 1992; 66: 983-91.
117. Benn J, Schneider RJ. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc. Natl Acad. Sci. USA 1994; 91: 10350-4.
118. Benn J, Su F, Doria M, Schneider RJ. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-related and c-Jun N-terminal mitogen-activated protein kinases. J. Virol. 1996; 70: 4978-85.
119. Henkler F, Lopes AR, Jones M, Koshy R. Erk-independent partial activation of AP-1 sites by the hepatitis B virus HBx protein. J. Gen. Virol. 1998; 79: 2737-42.
120. Klein NP, Schneider RJ. Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras. Mol. Cell. Biol. 1997; 17: 6427-36.
121. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 1997; 13: 513-609.
122. Benn J, Schneider RJ. Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc. Natl Acad. Sci. USA 1995; 92: 11 215-19.
123. Yu CL, Meyer DJ, Campbell GS et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995; 269: 81-3.
124. Campbell GS, Yu CL, Jove R, Carter-Su C. Constitutive activation of JAK1 in Src-transformed cells. J. Biol. Chem. 1997; 272: 2591-4.
125. Pellegrini S, Dusanter-Fourt I. The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs). Eur. J. Biochem. 1997; 249: 615-33.
126. Leonard WJ, O'Shea JJ. JAKS and STATS. Biological implications. Annu. Rev. Immunol. 1998; 16: 293-322.
127. Ransohoff RM. Cellular responses to interferons and other cytokines: The JAK-STAT paradigm. N. Engl. J. Med. 1998; 338: 616-18.
128. Lee Y-H, Yun Y. HBx protein of hepatitis B virus activates JAK1-STAT signaling. J. Biol. Chem. 1998; 273: 25 510-15.
129. Ruff-Jamison S, Chen K, Cohen S. Epidermal growth factor induces the tyrosine phosphorylation and nuclear translocation of Stat 5 in mouse liver. Proc. Natl Acad. Sci. USA 1995; 92: 4215-18.
130. Cressman DE, Diamond RH, Taub R. Rapid activation of the Stat3 transcription complex in liver regeneration. Hepatology 1995; 5: 1443-9.